iTeos Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- iTeos Therapeutics, Inc. (Nasdaq: ITOS) is a clinical-stage biopharmaceutical company focused on discovering and developing immuno-oncology therapeutics targeting tumor microenvironment resistance mechanisms for cancer patients, particularly solid tumors; its lead product candidate, belrestotug (EOS-448/GSK4428859A), is a TIGIT antagonist monoclonal antibody in Phase 3 trials (GALAXIES Lung-301) in combination with dostarlimab for first-line PD-L1 high non-small cell lung cancer and Phase 2 trials (GALAXIES Lung-201, GALAXIES H&N-202, TIG-006) for non-small cell lung cancer and head and neck squamous cell carcinoma, partnered globally with GlaxoSmithKline (GSK) under a 2021 collaboration agreement providing an upfront $625 million payment, potential milestones up to $1.45 billion (including a $35 million milestone in 2024 for GALAXIES Lung-301 first patient dosing), U.S. co-commercialization with profit split, and tiered royalties up to 20% ex-U.S.; EOS-984 is a first-in-class small molecule ENT1 inhibitor in Phase 1 (APT-008) for advanced malignancies as monotherapy and with pembrolizumab; EOS-215 is a best-in-class TREM2 antagonist monoclonal antibody advancing to Phase 1 (TRM-010) monotherapy for advanced malignancies; the inupadenant (EOS-850) A2A receptor antagonist program presented interim Phase 2 data in December 2024 but was deprioritized for insufficient clinical activity. Founded in 2011 as a Ludwig Cancer Research spin-off with initial operations in Gosselies, Belgium, the company is headquartered at 321 Arsenal Street, Watertown, Massachusetts, maintains a research center in Gosselies, Belgium, and employs approximately 173 people serving global markets through clinical trials in the United States and Europe. In July 2025, iTeos entered a definitive merger agreement with Concentra Biosciences, LLC, providing for acquisition at $10.047 per share in cash plus a non-transferable contingent value right (CVR) entitling holders to 100% of excess closing net cash above $475 million and 80% of net proceeds from specified asset sales (e.g., EOS-984, EOS-215 programs) within defined periods if conditions are met, with the tender offer expiring August 28, 2025 (extendable to October 16, 2025 outside date), no financing condition backed by a $465 million Tang Capital guaranty, and board unanimous recommendation supported by a TD Cowen fairness opinion; following a May 2025 announcement to wind down operations and explore asset sales, the company completed the merger, delisted from Nasdaq, and now operates as a Concentra subsidiary.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and KLG on Behalf of Shareholders
ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS
ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of iTeos Therapeutics, Inc. (NASDAQ: ITOS)
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
iTeos Therapeutics Announces Its Intention to Wind Down Operations
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
iTeos to Participate in Upcoming Investor Conferences